上海奥浦迈生物科技股份有限公司 2025年第三季度报告

Core Viewpoint - The company reported a significant increase in revenue for the first three quarters of 2025, with a focus on its core business of cell culture products, while also addressing challenges in its CDMO service segment [8][9][10]. Financial Performance - For the first three quarters of 2025, the company achieved operating revenue of 271.53 million yuan, a year-on-year increase of 25.79% [8]. - The main business revenue reached 271.18 million yuan, reflecting a growth of 25.83% compared to the same period last year [8]. - The cell culture products segment generated 238.60 million yuan in revenue, marking a significant growth of 32.56% year-on-year [8][9]. Business Segments - The CDMO service segment reported revenue of 32.58 million yuan, showing a slight decline due to external environmental factors and fluctuations in customer demand [9]. - The company has 311 confirmed drug development pipelines utilizing its cell culture media products, an increase of 64 compared to the end of 2024 [9]. Innovation and Recognition - The company's "Aopumai Antibody Series Culture Medium" was selected as a model case for innovative product application in the Yangtze River Delta region, highlighting its technological innovation and application value [10]. Quality Assurance - The company's wholly-owned subsidiary, Shanghai Silun Biotechnology Co., Ltd., successfully passed the EU Qualified Person audit, confirming compliance with EU GMP requirements [11]. Asset Restructuring - The company is in the process of a major asset restructuring, having responded to inquiries from regulatory bodies and is awaiting further approvals [12]. Asset Impairment - The company plans to recognize a total of 3.85 million yuan in asset impairment losses for the first three quarters of 2025, including credit impairment losses and inventory write-downs [23][24][25].